2024
Survivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations
Hart N, Nekhlyudov L, Smith T, Yee J, Fitch M, Crawford G, Koczwara B, Ashbury F, Lustberg M, Mollica M, Smith A, Jefford M, Chino F, Zon R, Agar M, Chan R. Survivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations. Supportive Care In Cancer 2024, 32: 313. PMID: 38679639, PMCID: PMC11056340, DOI: 10.1007/s00520-024-08465-8.Peer-Reviewed Original ResearchConceptsQuality survivorship careSurvivorship carePractice recommendationsUnmet supportive care needsPalliative care frameworkSupportive care needsSystematic reviewModified Delphi consensus processEnd-of-lifeResultsA systematic reviewDelphi consensus processMethodsAn expert panelCancer survivorshipCare goalsCancer careCare experiencesCare needsCare frameworkHealth outcomesASCO membersConsensus processCareDelphi studyExpert panelMetastatic cancer
2015
Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach
Reinbolt R, Mangini N, Hill J, Levine L, Dempsey J, Singaravelu J, Koehler K, Talley A, Lustberg M. Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach. Seminars In Oncology Nursing 2015, 31: 146-155. PMID: 25951743, DOI: 10.1016/j.soncn.2015.02.002.Peer-Reviewed Original ResearchConceptsEndocrine therapyBreast cancerMetastatic breast cancer settingLong-term disease outcomesHormone-positive breast cancerBreast cancer settingPositive breast cancerNeoadjuvant therapyTherapy adherenceClinical guidelinesSymptom interventionCancer settingDisease outcomeClinical considerationsOptimal durationNursing practiceTherapyCancerAdditional researchPivotal roleTreatmentNational statisticsNeoadjuvantAdjuvantSymptoms
2014
Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients
Lustberg M, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae E, Wesolowski R, Layman R, Mrozek E, Pan X, Summers T, Shapiro C, Chalmers J. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Research 2014, 16: r23. PMID: 24602188, PMCID: PMC4053256, DOI: 10.1186/bcr3622.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CDAntigens, Differentiation, MyelomonocyticAntigens, NeoplasmBiomarkers, TumorBreast NeoplasmsCell Adhesion MoleculesCell Line, TumorEpithelial Cell Adhesion MoleculeErbB ReceptorsFemaleFlow CytometryHumansImmunohistochemistryKeratin-18Keratin-19Keratin-8Leukocyte Common AntigensMCF-7 CellsMicroscopy, ConfocalMiddle AgedNeoplasm MetastasisNeoplastic Cells, CirculatingPrognosisProspective StudiesVimentinConceptsMetastatic breast cancerBreast cancer patientsBlood samplesCancer patientsBreast cancerMetastatic breast cancer patientsPatient samplesMultiparametric flow cytometry analysisAtypical cell populationNumber of CKPresent prospective trialWorse overall survivalTumor-associated macrophagesCell populationsPan-hematopoietic marker CD45Confocal microscopyEpidermal growth factor receptorEpithelial cell adhesion moleculeNormal control samplesCell surface markersRole of EpCAMFlow cytometry analysisGrowth factor receptorOverall survivalProspective trial
2013
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
Layman R, Ruppert A, Lynn M, Mrozek E, Ramaswamy B, Lustberg M, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut E, Shapiro C. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemotherapy And Pharmacology 2013, 71: 1183-1190. PMID: 23430121, PMCID: PMC3710373, DOI: 10.1007/s00280-013-2112-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBreast NeoplasmsCD4 Lymphocyte CountDose-Response Relationship, DrugErbB ReceptorsErlotinib HydrochlorideFemaleHumansLymphopeniaMiddle AgedNeoplasm MetastasisNitrogen Mustard CompoundsQuinazolinesSeverity of Illness IndexConceptsDose level 2Negative breast cancerCD4 countProlonged lymphopeniaBreast cancerMetastatic triple-negative breast cancerPurposeTriple-negative breast cancerEpidermal growth factor receptor expressionTriple-negative breast cancerEGFR tyrosine kinase inhibitorsDepressed CD4 countGrade 3/4 lymphopeniaDose level 1ECOG performance statusGrowth factor receptor expressionPhase I trialTyrosine kinase inhibitorsFactor receptor expressionHigh epidermal growth factor receptor (EGFR) expressionBendamustine combinationsConclusionsCombination therapyIntravenous bendamustineOral erlotinibPrior chemotherapyMetastatic disease
2012
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes
Lustberg M, Pant S, Ruppert A, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen R, Berger M, Mrozek E, Ramaswamy B, Grever M, Au J, Wientjes M, Shapiro C. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemotherapy And Pharmacology 2012, 70: 49-56. PMID: 22729159, PMCID: PMC3466596, DOI: 10.1007/s00280-012-1887-x.Peer-Reviewed Original ResearchConceptsObjective response rateMetastatic breast cancerWeekly paclitaxelAnti-tumor activityII trialBreast cancerPhase I/II trialMedian progression-free survivalGrowth factorPhase IMedian overall survivalResultsThirty-one patientsPhase II trialProgression-free survivalDose-limiting toxicityBasic fibroblast growth factorPre-specified criteriaNon-cytotoxic dosesFibroblast growth factorPrior taxaneMetastatic settingUnacceptable toxicityOverall survivalPolypeptide growth factorsSuramin concentrations